Cost Effectiveness of Eplerenone in Patients with Chronic Heart Failure
Zanfina Ademi, Kumar Pasupathi, Henry Krum, Danny Liew
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | ADIS INT LTD | Published : 2014
BACKGROUND: Chronic heart failure (CHF) remains an important cause of morbidity and mortality worldwide. Currently, there are no cost-effectiveness studies of eplerenone use in patients with New York Heart Association (NYHA) class II CHF. OBJECTIVE: We sought to evaluate the cost effectiveness of eplerenone compared with placebo in patients with chronic systolic heart failure and NYHA class II symptoms. METHODS AND RESULTS: A 10-year Markov model with yearly cycles was constructed to evaluate the cost effectiveness of eplerenone compared with placebo, based on data from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) study. The model classifi..View full abstract
Zanfina Ademi declares no conflict of interest. Kumar Pasupathi acknowledges funding from Pfizer for part-time employment on unrelated health economic projects. Henry Krum has received travel support as part of the steering committee for EMPHASIS-HF. Danny Liew has received honoraria and research grants from Pfizer Australia.